DK2764099T3 - ECM composition, tumor microenvironmental platforms, and method thereof - Google Patents

ECM composition, tumor microenvironmental platforms, and method thereof Download PDF

Info

Publication number
DK2764099T3
DK2764099T3 DK12838648.9T DK12838648T DK2764099T3 DK 2764099 T3 DK2764099 T3 DK 2764099T3 DK 12838648 T DK12838648 T DK 12838648T DK 2764099 T3 DK2764099 T3 DK 2764099T3
Authority
DK
Denmark
Prior art keywords
tumor
approx
response
tissue
drug
Prior art date
Application number
DK12838648.9T
Other languages
Danish (da)
English (en)
Inventor
Mallikarjun Sundaram
Biswanath Majumder
Misti Jain
Saravanan Thiagarajan
Dency Pinto
Padhma Radhakrishnan
Original Assignee
Mitra Rxdx India Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitra Rxdx India Private Ltd filed Critical Mitra Rxdx India Private Ltd
Application granted granted Critical
Publication of DK2764099T3 publication Critical patent/DK2764099T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DK12838648.9T 2011-10-04 2012-10-04 ECM composition, tumor microenvironmental platforms, and method thereof DK2764099T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3310CH2011 2011-10-04
PCT/IB2012/055334 WO2013050962A1 (en) 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof

Publications (1)

Publication Number Publication Date
DK2764099T3 true DK2764099T3 (en) 2018-02-26

Family

ID=54261176

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12838648.9T DK2764099T3 (en) 2011-10-04 2012-10-04 ECM composition, tumor microenvironmental platforms, and method thereof

Country Status (14)

Country Link
US (7) US20140228246A1 (enExample)
EP (1) EP2764099B1 (enExample)
JP (2) JP6147259B2 (enExample)
AU (1) AU2012320088C1 (enExample)
CA (1) CA2850274A1 (enExample)
CY (1) CY1120087T1 (enExample)
DK (1) DK2764099T3 (enExample)
ES (1) ES2660975T3 (enExample)
HU (1) HUE036537T2 (enExample)
NO (1) NO2764099T3 (enExample)
PT (1) PT2764099T (enExample)
SG (1) SG11201401183UA (enExample)
TR (1) TR201802420T4 (enExample)
WO (1) WO2013050962A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105593438B (zh) 2013-05-31 2019-07-05 伊顿智能动力有限公司 用于通过平衡保护来降低动臂跳动的液压系统及方法
AU2014354599A1 (en) * 2013-11-27 2016-06-09 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
CN103966168B (zh) * 2014-05-19 2017-05-03 广州恒迪生物科技有限公司 肿瘤活组织体外培养系统及培养方法
WO2016154082A2 (en) * 2015-03-23 2016-09-29 Tang Yao Methods of primary tissue culture and drug screening using autologous serum and fluids
GB2555252A (en) * 2015-04-22 2018-04-25 Ono Pharmaceutical Co Method for extracting lead compound, method for selecting drug discovery target, device for generating scatter diagram, and data visualization method
GB201507894D0 (en) * 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
KR102757122B1 (ko) * 2015-10-20 2025-01-21 셀퀴티 인크. 1차 세포 샘플을 제조하는 방법
CN106047788A (zh) * 2016-08-22 2016-10-26 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的培养基
GB2555787A (en) 2016-11-07 2018-05-16 Landberg Goran Diagnostic methods
WO2018148336A1 (en) * 2017-02-08 2018-08-16 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
WO2018185760A1 (en) 2017-04-05 2018-10-11 Yeda Research And Development Co. Ltd. Ex-vivo culture system and methods of using same
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019164951A1 (en) * 2018-02-22 2019-08-29 Mitra Rxdx, Inc. Methods of predicting response to temporally sequenced combination therapy
GB201818885D0 (en) 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
WO2020172591A1 (en) * 2019-02-22 2020-08-27 Mitra Rxdx, Inc. A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes
CA3130930A1 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
CN112961830A (zh) * 2021-02-25 2021-06-15 重庆医科大学附属口腔医院 口腔鳞癌组织脱细胞基质及其制备方法和应用
CA3219233A1 (en) 2021-06-06 2022-12-15 Ravid STRAUSSMAN Combined treatment for cancer
CN113774025B (zh) * 2021-08-26 2023-07-14 湖南丰晖生物科技有限公司 一种结直肠癌顺铂耐药株的构建方法
WO2023067582A1 (en) * 2021-10-23 2023-04-27 Mazumdar Shaw Medical Foundation Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression
WO2023244699A1 (en) 2022-06-15 2023-12-21 SageMedic Corporation A high-throughput multiplexed viability and proliferation assay
PL444462A1 (pl) * 2023-04-18 2024-10-21 Uniwersytet Medyczny W Białymstoku Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
FR2842822B1 (fr) * 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
WO2008060377A2 (en) * 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
US20120213706A1 (en) * 2009-04-15 2012-08-23 University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
WO2011148669A1 (ja) * 2010-05-25 2011-12-01 株式会社 島津製作所 大腸がんマーカービトロネクチン、及び採血試料中のビトロネクチン濃度の分析方法

Also Published As

Publication number Publication date
JP6378273B2 (ja) 2018-08-22
ES2660975T3 (es) 2018-03-26
PT2764099T (pt) 2018-02-28
CY1120087T1 (el) 2018-12-12
US20190170730A1 (en) 2019-06-06
JP2014534809A (ja) 2014-12-25
JP2017061448A (ja) 2017-03-30
US20190383795A1 (en) 2019-12-19
US20140228246A1 (en) 2014-08-14
NO2764099T3 (enExample) 2018-04-21
AU2012320088B9 (en) 2015-07-16
JP6147259B2 (ja) 2017-06-14
AU2012320088A1 (en) 2014-05-01
CA2850274A1 (en) 2013-04-11
TR201802420T4 (tr) 2018-03-21
AU2012320088B2 (en) 2015-07-02
HUE036537T2 (hu) 2018-07-30
WO2013050962A1 (en) 2013-04-11
SG11201401183UA (en) 2014-09-26
AU2012320088C1 (en) 2016-03-17
US20190353640A1 (en) 2019-11-21
EP2764099A1 (en) 2014-08-13
US20200064333A1 (en) 2020-02-27
US20190346428A1 (en) 2019-11-14
EP2764099A4 (en) 2015-05-06
US20190383796A1 (en) 2019-12-19
EP2764099B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
DK2764099T3 (en) ECM composition, tumor microenvironmental platforms, and method thereof
JP7330235B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
JP6580546B2 (ja) 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法
Fernandez et al. Multi-institutional study of pathologist reading of the programmed cell death ligand-1 combined positive score immunohistochemistry assay for gastric or gastroesophageal junction cancer
WO2011047019A9 (en) An objective, quantitative method to predict histological subtype in non-small cell lung cancer
Onoda et al. Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors
Pegolo et al. One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasis
Skarlos et al. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
CN111886499B (zh) 基于检测肿瘤细胞中rad51焦点的方法
Parrish et al. Differential localization of β-catenin protein in CTNNB1 mutant endometrial cancers results in distinct transcriptional profiles
Chiappori et al. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
WO2019057913A1 (en) METHOD AND KITS FOR THE PROGNOSIS OF SQUAMOUS CARCINOMA PULMONARY (SCC)
Charpin et al. Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas
WO2019057919A1 (en) METHODS AND KITS FOR THE PROGNOSIS OF LUNG ADENOCARCINOMA
Liedtke et al. Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes
Kuroda et al. Vascular invasion in triple-negative carcinoma of the breast identified by endothelial lymphatic and blood vessel markers
Tebbit et al. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care
Usui et al. Modeling canine hemangiosarcoma progression using patient-derived 2.5 D organoids and orthotopic xenografts
Mastroianni et al. Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivodrug screening
Klimaszewska-Wisniewska et al. Zabrzy nski, J
Cristofanilli CTC in Advanced Breast Cancer Prognosis, Monitoring, and Clinical Utility
Miceli et al. Application of a New Classification to a Breast Tumor Series from a Population-Based Cancer Registry